Q1 Earnings Estimate for CLDX Issued By HC Wainwright

Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) - Equities researchers at HC Wainwright issued their Q1 2025 earnings per share (EPS) estimates for Celldex Therapeutics in a report issued on Friday, February 28th. HC Wainwright analyst J. Pantginis forecasts that the biopharmaceutical company will post earnings per share of ($0.73) for the quarter. HC Wainwright currently has a "Buy" rating and a $80.00 price target on the stock. The consensus estimate for Celldex Therapeutics' current full-year earnings is ($2.48) per share.

CLDX has been the subject of several other research reports. The Goldman Sachs Group cut their target price on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating for the company in a research report on Monday. UBS Group began coverage on Celldex Therapeutics in a research report on Thursday, February 13th. They set a "buy" rating and a $44.00 target price for the company. Finally, Cantor Fitzgerald restated an "overweight" rating and set a $67.00 price target on shares of Celldex Therapeutics in a report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $55.38.

Celldex Therapeutics Price Performance

Shares of NASDAQ:CLDX traded up $0.23 during trading on Monday, hitting $21.33. 757,450 shares of the company's stock were exchanged, compared to its average volume of 907,459. Celldex Therapeutics has a 52-week low of $18.61 and a 52-week high of $49.65. The business's 50-day simple moving average is $23.48 and its 200 day simple moving average is $28.59. The company has a market cap of $1.42 billion, a price-to-earnings ratio of -8.30 and a beta of 1.76.

Remove Ads

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last posted its quarterly earnings data on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02. Celldex Therapeutics had a negative return on equity of 19.75% and a negative net margin of 1,544.32%. The firm had revenue of $1.18 million for the quarter, compared to the consensus estimate of $1.25 million.

Institutional Investors Weigh In On Celldex Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the business. KBC Group NV lifted its stake in shares of Celldex Therapeutics by 31.2% during the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company's stock worth $71,000 after acquiring an additional 495 shares during the last quarter. Invesco Ltd. lifted its stake in shares of Celldex Therapeutics by 2.1% during the 4th quarter. Invesco Ltd. now owns 42,101 shares of the biopharmaceutical company's stock worth $1,064,000 after acquiring an additional 871 shares during the last quarter. EverSource Wealth Advisors LLC lifted its stake in shares of Celldex Therapeutics by 215.7% during the 4th quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company's stock worth $32,000 after acquiring an additional 878 shares during the last quarter. Swiss National Bank lifted its stake in shares of Celldex Therapeutics by 1.2% during the 4th quarter. Swiss National Bank now owns 117,300 shares of the biopharmaceutical company's stock worth $2,964,000 after acquiring an additional 1,400 shares during the last quarter. Finally, Teachers Retirement System of The State of Kentucky lifted its stake in shares of Celldex Therapeutics by 5.1% during the 3rd quarter. Teachers Retirement System of The State of Kentucky now owns 42,628 shares of the biopharmaceutical company's stock worth $1,449,000 after acquiring an additional 2,070 shares during the last quarter.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.